Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children-Reference-Cited by-同舟云学术

Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children

Published:2023-02-28 Issue: Volume:2023 Page:1-4
ISSN:2090-6439
Container-title:Case Reports in Critical Care
language:en
Short-container-title:Case Reports in Critical Care

Author:

Alolayan Abdulaziz¹^ORCID,Aldamegh Abdullah S.²,Alkhayrat Azzah¹

Affiliation:

1. Pharmacy Department, Prince Sultan Military Medical City, Saudi Arabia

2. Pediatrics Department, Unaizah College of Medicine and Medical Sciences, Al-Qassim University, Saudi Arabia

Abstract

Coronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress the exaggerated inflammatory response in such conditions, and it is potentially lifesaving in a cytokine storm. We present the case of a patient with critical COVID-19 associated with multisystem inflammatory syndrome in children (MIS-C) successfully treated with anakinra intravenous (IV) infusion.

Funder

Prince Sultan Military Medical City

Publisher

Hindawi Limited

Subject

Critical Care and Intensive Care Medicine

Link

http://downloads.hindawi.com/journals/cricc/2023/8530060.pdf

Reference24 articles.

1. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series

2. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19;Royal College of Pediatrics and Child Health,2020

3. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

4. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study